Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation

Keyphrases

• Pediatric Hematopoietic Stem Cell Transplantation 100%
• Clinical Outcomes 100%
• Cyclosporine 100%
• Tacrolimus 100%
• Neurotoxicity 50%
• Engraftment Syndrome 37%
• Graft-versus-host Disease (GvHD) 37%
• Hypertension 25%
• Vomiting 25%
• Hepatotoxicity 25%
• Calcineurin Inhibitors 25%
• Hematopoietic Stem Cell Transplantation 25%
• GVHD Prophylaxis 25%
• Nephrotoxicity 25%
• Immunosuppression 12%
• Response Rate 12%
• Adverse Events 12%
• Posterior Reversible Encephalopathy Syndrome 12%
• Allergic Reaction 12%
• Pediatric 12%
• Mechanism of Action 12%
• Organ Toxicity 12%
• Host Disease 12%
• Retrospective Analysis 12%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 12%
• Antalya 12%

Medicine and Dentistry

• Hematopoietic Stem Cell Transplantation 100%
• Cyclosporine 100%
• Tacrolimus 100%
• Neurotoxicity 50%
• Engraftment Syndrome 37%
• Calcineurin Inhibitor 25%
• Transplantation 25%
• Liver Toxicity 25%
• Acute Graft Versus Host Disease 25%
• Stem Cell Therapy 25%
• Nephrotoxicity 25%
• Adverse Event 12%
• Allogeneic Hematopoietic Stem Cell Transplantation 12%
• Spine 12%
• Conversion Therapy 12%
• Allergic Response 12%
• Organ Toxicity 12%
• Immunosuppressive Treatment 12%
• Posterior Reversible Encephalopathy Syndrome 12%
• Host 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Ciclosporin 100%
• Tacrolimus 100%
• Neurotoxicity 50%
• Engraftment Syndrome 37%
• Nephrotoxicity 25%
• Hepatotoxicity 25%
• Calcineurin Inhibitor 25%
• Acute Graft Versus Host Disease 25%
• Organ Toxicity 12%
• Adverse Event 12%
• Allergic Reaction 12%
• Host 12%
• Posterior Reversible Encephalopathy Syndrome 12%